Related Experiment Videos
Pharmacogenetic screening and therapeutic drugs
Werner Steimer1, Julia M Potter
1Institute for Clinical Chemistry and Pathobiochemistry, Munich University of Technology, Klinikum rechts der Isar, Ismaningerstrasse 22, D-81675 Munich, Germany. Steimer@KlinChem.med.TU-Muenchen.de
Background:
Pharmacogenetics is the science of the influence of heredity on pharmacological response.
Issues:
The cost of severe adverse drug reactions in individuals has been estimated in the US alone to be in excess of US$4 billion. It has been argued that in a significant proportion of cases, the efficacy and toxicity profiles of drug therapy would be substantially improved in individuals if characteristics due to genetic variation were taken into account. Methods are now available, which make screening for susceptibility feasible.
Conclusions:
There are several therapeutic areas in which screening may give rise to significant improvements in outcome with cost-benefits to both the individual and the community. However, there is currently a lack of data on which cost-benefit analysis can be based. The challenge is to provide this information for new drugs, and for drugs with established therapeutic roles.